Sulpiride-induced tardive dystonia
Identifieur interne : 003988 ( PascalFrancis/Corpus ); précédent : 003987; suivant : 003989Sulpiride-induced tardive dystonia
Auteurs : L. G. Miller ; J. JankovicSource :
- Movement disorders [ 0885-3185 ] ; 1990.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 90-0168298 INIST |
---|---|
ET : | Sulpiride-induced tardive dystonia |
AU : | MILLER (L. G.); JANKOVIC (J.) |
AF : | Baylor coll. medicine, dep. family medicine/Houston TX 77030/Etats-Unis (A11011000) |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1990; Vol. 5; No. 1; Pp. 83-84; Bibl. 19 ref. |
LA : | Anglais |
EA : | We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy |
CC : | 002B02U01 |
FD : | Sulpiride; Antagoniste dopamine; Récepteur dopaminergique D2; Antidépresseur; Homme; Dystonie; Tardif; Psychotrope; Toxicité; Système nerveux pathologie; Etude cas |
ED : | Dopamine antagonist; D2 Dopamine receptor; Antidepressant agent; Human; Dystonia; Late; Psychotropic; Toxicity; Nervous system diseases; Case study |
SD : | Antagonista dopamina; Receptor dopaminérgico D2; Antidepresor; Hombre; Distonía; Tardío; Psicotropo; Toxicidad; Sistema nervioso patología; Estudio caso |
LO : | CNRS-20953 |
ID : | 90-0168298 |
Links to Exploration step
Pascal:90-0168298Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Sulpiride-induced tardive dystonia</title>
<author><name sortKey="Miller, L G" sort="Miller, L G" uniqKey="Miller L" first="L. G." last="Miller">L. G. Miller</name>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">J. Jankovic</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">90-0168298</idno>
<date when="1990">1990</date>
<idno type="stanalyst">PASCAL 90-0168298 INIST</idno>
<idno type="RBID">Pascal:90-0168298</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003988</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Sulpiride-induced tardive dystonia</title>
<author><name sortKey="Miller, L G" sort="Miller, L G" uniqKey="Miller L" first="L. G." last="Miller">L. G. Miller</name>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">J. Jankovic</name>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1990">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressant agent</term>
<term>Case study</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine antagonist</term>
<term>Dystonia</term>
<term>Human</term>
<term>Late</term>
<term>Nervous system diseases</term>
<term>Psychotropic</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Sulpiride</term>
<term>Antagoniste dopamine</term>
<term>Récepteur dopaminergique D2</term>
<term>Antidépresseur</term>
<term>Homme</term>
<term>Dystonie</term>
<term>Tardif</term>
<term>Psychotrope</term>
<term>Toxicité</term>
<term>Système nerveux pathologie</term>
<term>Etude cas</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>5</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Sulpiride-induced tardive dystonia</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MILLER (L. G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JANKOVIC (J.)</s1>
</fA11>
<fA14 i1="01"><s1>Baylor coll. medicine, dep. family medicine</s1>
<s2>Houston TX 77030</s2>
<s3>USA</s3>
<sZ>A11011000</sZ>
</fA14>
<fA20><s1>83-84</s1>
</fA20>
<fA21><s1>1990</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>CNRS</s1>
<s2>20953</s2>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>90-0168298</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Sulpiride</s0>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Antagoniste dopamine</s0>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antidépresseur</s0>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Dystonie</s0>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Tardif</s0>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Psychotrope</s0>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Toxicité</s0>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Etude cas</s0>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dopamine antagonist</s0>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antidepressant agent</s0>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dystonia</s0>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Late</s0>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Psychotropic</s0>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Toxicity</s0>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Nervous system diseases</s0>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Case study</s0>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Antagonista dopamina</s0>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antidepresor</s0>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Distonía</s0>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tardío</s0>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Psicotropo</s0>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Toxicidad</s0>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Estudio caso</s0>
</fC03>
<fC04 i1="01" i2="X"><s0>PU01!16,06,07</s0>
</fC04>
<fC04 i1="02" i2="X"><s0>PU06,07!16,01</s0>
</fC04>
<fN21><s1>009</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 90-0168298 INIST</NO>
<ET>Sulpiride-induced tardive dystonia</ET>
<AU>MILLER (L. G.); JANKOVIC (J.)</AU>
<AF>Baylor coll. medicine, dep. family medicine/Houston TX 77030/Etats-Unis (A11011000)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1990; Vol. 5; No. 1; Pp. 83-84; Bibl. 19 ref.</SO>
<LA>Anglais</LA>
<EA>We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy</EA>
<CC>002B02U01</CC>
<FD>Sulpiride; Antagoniste dopamine; Récepteur dopaminergique D2; Antidépresseur; Homme; Dystonie; Tardif; Psychotrope; Toxicité; Système nerveux pathologie; Etude cas</FD>
<ED>Dopamine antagonist; D2 Dopamine receptor; Antidepressant agent; Human; Dystonia; Late; Psychotropic; Toxicity; Nervous system diseases; Case study</ED>
<SD>Antagonista dopamina; Receptor dopaminérgico D2; Antidepresor; Hombre; Distonía; Tardío; Psicotropo; Toxicidad; Sistema nervioso patología; Estudio caso</SD>
<LO>CNRS-20953</LO>
<ID>90-0168298</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003988 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003988 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:90-0168298 |texte= Sulpiride-induced tardive dystonia }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |